The health-related quality-of-life of chronic obstructive pulmonary disease patients and disease-related indirect burdens

Choi, Hye Sook; Yang, Dong‐Jin; Rhee, Chin Kook; Yoon, Hyoung Kyu; Lee, Jin Hwa; Lim, Seong Yong; Kim, Yu Il; Yoo, Kwang Ha; Hwang, Yong Il; Lee, Sang Haak; Park, Yong Bum

doi:10.3904/kjim.2018.398

Cited by 9 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that the proportion of healthcare utilization increased across grades of airflow limitation, as observed previously. 28 However, for participants who visited GPs or hospitalizations in 12 months, the number of GP visits and hospitalizations was not significantly different across the four groups. These results may be attributed to the small number of participants in the GOLD 2 and GOLD 3 or 4 group.…”

Section: Discussionmentioning

confidence: 84%

Respiratory Symptoms, Disease Burden, and Quality of Life in Australian Adults According to GOLD Spirometry Grades: Data from the BOLD Australia Study

Zhou,

Ampon,

Abramson

et al. 2023

COPD

View full text Add to dashboard Cite

Purpose Population data on the burden of chronic obstructive pulmonary disease (COPD) are often based on patient-reported diagnoses of COPD, emphysema or chronic bronchitis, without spirometry. We aimed to investigate the relationship between health burden, quality of life and severity of airway obstruction in Australian adults aged ≥40 years. Methods We used data from the BOLD Australia study, which included randomly selected adults aged ≥40 years from six study sites to reflect the sociodemographic and geographic diversity of the Australian population (n = 3522). Participants with post-bronchodilator airflow limitation (ratio of forced expiratory volume in 1 second FEV 1 to forced vital capacity <0.7) were grouped by GOLD spirometry grades 1–4. Quality of life was assessed with Short Form 12 (SF-12) Health Survey Questionnaire. Health burden was assessed as lost time off work or social activities, and healthcare utilization. Results Of the study sample, 2969 participants did not have airflow limitation, 294 (8.4%) were classified as GOLD Grade 1, 212 (6.0%) as GOLD 2 and 43 (1.2%) as GOLD 3–4. Participants with higher GOLD grades had more respiratory symptoms, more comorbidities and greater burden than those with lower GOLD grades. The scores of mental and physical subscales of SF-12 were lower, indicating worse quality of life, from the no airflow limitation group to the GOLD 3–4 group (P = 0.03 and P < 0.001, respectively). Conclusion Greater airflow limitation is associated with greater burden and poor quality of life. Interventions to prevent, or reduce the level of, airflow limitation will reduce the symptom burden and improve quality of life for patients.

show abstract

Section: Discussionmentioning

confidence: 84%

Respiratory Symptoms, Disease Burden, and Quality of Life in Australian Adults According to GOLD Spirometry Grades: Data from the BOLD Australia Study

Zhou,

Ampon,

Abramson

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

“…Each dimension has a five-level response corresponding to no problem, slight problems, moderate problems, severe problems, and extreme problems. 24 …”

Section: Methodsmentioning

confidence: 99%

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

Park¹,

Hong²,

Rhee³

et al. 2023

COPD

Self Cite

View full text Add to dashboard Cite

Background A comprehensive analysis of the effects of inhaled corticosteroids (ICS) on COPD in a real-world setting is required due to safety concerns regarding ICS in COPD. This study aimed to explore the impact of ICS on the prognosis of Asian COPD patients in the real-life world. Methods We examined 978 COPD patients registered in the Korean National Health and Nutrition Examination Survey (KNHANES) database and with their data linked to Health Insurance and Review Assessment (HIRA) data. The outcome measures were ascertained by HIRA from January 1, 2009, to December 31, 2012. This study enrolled two arms; ICS users (N = 85, mean age = 66.7 ± 8.9 years) and non-ICS users (N = 893, mean age = 63.7 ± 9.7 years). Results Compared to the non-ICS users, the ICS users had a higher rate of pneumonia, tuberculosis, and acute exacerbations ( P <0.05). Hospitalization due to respiratory causes was also higher among ICS users ( P <0.05). Multivariate analysis showed that acute exacerbation was independently associated with the development of pneumonia ( P <0.05), whereas ICS therapy had a tendency to be associated with pneumonia. Another multivariate analysis demonstrated that old age, FEV 1 , ICS therapy, and pneumonia were independently associated with the occurrence of acute exacerbation ( P <0.05). The concomitant pneumonia (HR = 3.353, P = 0.004) was independently associated with higher mortality ( P <0.05). Conclusion Our data demonstrated that the ICS users had a higher rate of pneumonia and tuberculosis and the concomitant pneumonia was independently associated with higher mortality, highlighting the importance of cautious and targeted administration of ICS in COPD.

show abstract

“…A major component of healthcare expenditure is the cost of medication, diagnostics, treatments and hospitalisation. There is also a significant social burden in productivity loss, informal care and loss of Quality-Adjusted Life Years (QALYs) [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial

et al. 2023

View full text Add to dashboard Cite

Objective The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run. Method The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the primary analysis compared the costs and effectiveness of PHC telehealth monitoring with usual care. An incremental cost-effectiveness ratio was calculated based on costs and health-related quality of life. The PHC intervention was implemented in the Barwon Health region, Geelong, Australia, for patients with a diagnosis of COPD and/or diabetes who had a high likelihood of hospital readmission over 12 months. Results When compared to usual care at 12 months, the PHC intervention cost AUD$714 extra per patient (95%CI -4879; 6308) with a significant improvement of 0.09 in health-related quality of life (95%CI: 0.05; 0.14). The probability of PHC being cost-effective by 12 months was close to 65%, at willingness to pay a threshold of AUD$50,000 per quality-adjusted life year. Conclusion Benefits of PHC to patients and the health system at 12 months translated to a gain in quality-adjusted life years with a non-significant cost difference between the intervention and control groups. Given the relatively high set-up costs of the PHC intervention, the program may need to be offered to a larger population to achieve cost-effectiveness. Long-term follow-up is required to assess the real health and economic benefits over time.

show abstract

The health-related quality-of-life of chronic obstructive pulmonary disease patients and disease-related indirect burdens

Cited by 9 publications

References 22 publications

Respiratory Symptoms, Disease Burden, and Quality of Life in Australian Adults According to GOLD Spirometry Grades: Data from the BOLD Australia Study

Respiratory Symptoms, Disease Burden, and Quality of Life in Australian Adults According to GOLD Spirometry Grades: Data from the BOLD Australia Study

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial

Contact Info

Product

Resources

About